Patents by Inventor Patricia S. Goldman-Rakic

Patricia S. Goldman-Rakic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of lofexidine in the treatment of behavioral disorders
    Patent number: 5863934
    Abstract: Disclosed is a method of treating disorders which have prominent symptoms of behavioral disinhibition (e.g., Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional Defiant Disorder, Tourette's Syndrome, Lesch-Nyhan Syndrome, or the disinhibitory symptoms accompanying Post-traumatic Stress Disorder or dementia) in a primate with minimal sedative side effects by administering thereto a therapeutically effective amount of lofexidine.
    Type: Grant
    Filed: October 17, 1996
    Date of Patent: January 26, 1999
    Assignees: Amy F. T. Arnsten, Patricia S. Goldman-Rakic, Robert H. Hunt
    Inventors: Amy F. T. Arnsten, Patricia S. Goldman-Rakic, Robert D. Hunt
  • Use of guanfacine in the treatment of behavioral disorders
    Patent number: 5854290
    Abstract: Disclosed is a method of treating disorders which have prominent symptoms of behavioral disinhibition (e.g., Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional Defiant Disorder, Tourette's Syndrome, Lesch-Nyhan Syndrome, or the disinhibitory symptoms accompanying Post-traumatic Stress Disorder or dementia) in a primate with minimal sedative side effects by administering thereto a therapeutically effective amount of guanfacine.
    Type: Grant
    Filed: September 21, 1995
    Date of Patent: December 29, 1998
    Assignees: Amy F. T. Arnsten, Patricia Goldman-Rakic, Robert H. Hunt
    Inventors: Amy F. T. Arnsten, Patricia S. Goldman-Rakic, Robert H. Hunt
  • Use of alpha-2I selective adrenergic receptor agonists in memory enhancement
    Patent number: 4847300
    Abstract: Disclosed is a method of treating memory disorders and cognitive decline, e.g., age-related cognitive decline, in a primate by administering thereto a therapeutically effective amount of an alpha-2 agonist having a high affinity for the alpha-2I subtype, e.g., guanfacine and guanabenz or a nontoxic, pharmaceutically acceptable salt thereof. Particularly preferred is the use of alpha-2I selective agonists such as guanfacine.
    Type: Grant
    Filed: November 7, 1986
    Date of Patent: July 11, 1989
    Assignee: Yale University
    Inventors: Amy F. T. Arnsten, Patricia S. Goldman-Rakic
  • Use of clonidine in memory enhancement
    Patent number: 4785014
    Abstract: Disclosed is a method of treating cognitive decline in a normal aged primate by administering thereto a therapeutically effective amount of 2-[(2,6-dichlorophenyl)-amino]-2-imidazoline or a nontoxic, pharmaceutically acceptable salt thereof. Administration is preferably in amounts of at least about 0.001 mg/day.
    Type: Grant
    Filed: November 6, 1986
    Date of Patent: November 15, 1988
    Assignee: Yale University
    Inventors: Patricia S. Goldman-Rakic, Amy F. T. Arnsten